Recent progress towards clinically relevant ATP-competitive Akt inhibitors

Bioorganic & Medicinal Chemistry Letters
Bayard R Huck, Igor Mochalkin

Abstract

The frequency of PI3K/Akt/mTOR (PAM) Pathway mutations in human cancers sparked interest to determine if the pathway is druggable. The modest clinical benefit observed with mTOR rapalogs (temsirolimus and everolimus) provided further motivation to identify additional nodes of pathway inhibition that lead to improved clinical benefit. Akt is a central signaling node of the PAM pathway and could be an ideal target for improved pathway inhibition. Furthermore, inhibitors of Akt may be especially beneficial in tumors with Akt1 mutations. Recently, multiple ATP-competitive Akt inhibitors have been identified and are currently in clinical development. This review details the medicinal chemistry efforts towards identification of these molecules, highlights relevant preclinical data supporting clinical evaluation, and summarizes current clinical development plans.

Citations

Jun 22, 2017·Journal of Cellular Biochemistry·Yanhong LuoHua Zhu
Nov 28, 2018·Journal of Biomolecular Structure & Dynamics·Elkin Eduardo Sanabria-ChanagaRafael Castillo
May 27, 2020·Biochemical Society Transactions·Glorianne LazaroIgor Vivanco
Oct 20, 2018·International Journal of Oncology·George Mihai NitulescuDenisa Margina
Sep 20, 2020·ESMO Open·Byung Woog Kang, Ian Chau
Mar 21, 2020·Frontiers in Pharmacology·Yi-Hui WuCheng-Yang Chou
Apr 26, 2020·Molecular Biology Reports·Ningni JiangJuan Peng
Jan 10, 2021·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Xiaotian QiRong Sun
Dec 21, 2019·Cell Chemical Biology·Inchul YouAlex Toker
Feb 13, 2021·International Journal of Molecular Sciences·Nadezhda V Popova, Manfred Jücker

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Current Opinion in Investigational Drugs
Shripad V Bhagwat, Andrew P Crew
Biochemical Pharmacology
Claudia FumarolaRoberta R Alfieri
Cancer Biology & Medicine
Joycelyn Jx LeeYoon-Sim Yap
Expert Opinion on Investigational Drugs
Angelica Fasolo, Cristiana Sessa
Reviews on Recent Clinical Trials
Aruni S Arachchige Don, X F Steven Zheng
© 2022 Meta ULC. All rights reserved